Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients : Results from a Spanish multicenter cohort
Copyright © 2021 American Society for Microbiology..
Current guidelines recommend against systematic screening or treating asymptomatic bacteriuria (AB) among kidney transplant (KT) recipients, although the evidence regarding episodes occurring early after transplantation or in the presence of anatomical abnormalities is inconclusive. Oral fosfomycin may constitute a good option for the treatment of post-transplant AB, particularly due to the emergence of multidrug-resistant (MDR) uropathogens. Available clinical evidence supporting its use in this specific setting, however, remains scarce. We performed a retrospective study in 14 Spanish institutions from January 2005 to December 2017. Overall, 137 episodes of AB diagnosed in 133 KT recipients treated with oral fosfomycin (calcium and trometamol salts) with a test-of-cure urine culture within the first 30 days were included. Median time from transplantation to diagnosis was 3.1 months (interquartile range [IQR]: 1.1 - 10.5). Most episodes (96.4% [132/137]) were caused by gram-negative bacteria (GNB), and 56.9% (78/137) were categorized as MDR (extended-spectrum β-lactamase-producing Enterobacterales [20.4%] and carbapenem-resistant GNB [2.9%]). Rate of microbiological failure at month 1 was 40.1% (95% confidence interval [95%CI]: 31.9 - 48.9) for the whole cohort and 42.3% (95%CI: 31.2 - 54.0) for episodes due to MDR pathogens. Previous urinary tract infection (odds ratio [OR]: 2.42; 95%CI: 1.11 - 5.29; P-value = 0.027) and use of fosfomycin as salvage therapy (OR: 8.31; 95%CI: 1.67 - 41.35; P-value = 0.010) were predictors of microbiological failure. No severe treatment-related adverse event were detected. Oral fosfomycin appears to be a suitable and safe alternative for the treatment (if indicated) of AB after KT, including those episodes due to MDR uropathogens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 95(2023), 5 vom: 01. Mai |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 28.02.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1128/AAC.02267-20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321187407 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321187407 | ||
| 003 | DE-627 | ||
| 005 | 20231225175258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.02267-20 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321187407 | ||
| 035 | |a (NLM)33558295 | ||
| 035 | |a (PII)AAC.02267-20 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruiz-Ruigómez, María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients |b Results from a Spanish multicenter cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 American Society for Microbiology. | ||
| 520 | |a Current guidelines recommend against systematic screening or treating asymptomatic bacteriuria (AB) among kidney transplant (KT) recipients, although the evidence regarding episodes occurring early after transplantation or in the presence of anatomical abnormalities is inconclusive. Oral fosfomycin may constitute a good option for the treatment of post-transplant AB, particularly due to the emergence of multidrug-resistant (MDR) uropathogens. Available clinical evidence supporting its use in this specific setting, however, remains scarce. We performed a retrospective study in 14 Spanish institutions from January 2005 to December 2017. Overall, 137 episodes of AB diagnosed in 133 KT recipients treated with oral fosfomycin (calcium and trometamol salts) with a test-of-cure urine culture within the first 30 days were included. Median time from transplantation to diagnosis was 3.1 months (interquartile range [IQR]: 1.1 - 10.5). Most episodes (96.4% [132/137]) were caused by gram-negative bacteria (GNB), and 56.9% (78/137) were categorized as MDR (extended-spectrum β-lactamase-producing Enterobacterales [20.4%] and carbapenem-resistant GNB [2.9%]). Rate of microbiological failure at month 1 was 40.1% (95% confidence interval [95%CI]: 31.9 - 48.9) for the whole cohort and 42.3% (95%CI: 31.2 - 54.0) for episodes due to MDR pathogens. Previous urinary tract infection (odds ratio [OR]: 2.42; 95%CI: 1.11 - 5.29; P-value = 0.027) and use of fosfomycin as salvage therapy (OR: 8.31; 95%CI: 1.67 - 41.35; P-value = 0.010) were predictors of microbiological failure. No severe treatment-related adverse event were detected. Oral fosfomycin appears to be a suitable and safe alternative for the treatment (if indicated) of AB after KT, including those episodes due to MDR uropathogens | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, José Tiago |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Origüen, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo-Cano, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Luna-Huerta, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Domingo |e verfasserin |4 aut | |
| 700 | 1 | |a Jironda-Gallegos, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Escudero-Sánchez, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Gioia, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Roca, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cordero, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Janeiro, Darío |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Sobrino, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, María Milagro |e verfasserin |4 aut | |
| 700 | 1 | |a Redondo, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Candel, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Flores, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Armiñanzas, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a González-Rico, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Fariñas, María Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigo, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Loeches, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a López-Oliva, María O |e verfasserin |4 aut | |
| 700 | 1 | |a Montejo, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Lauzurica, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Horcajada, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Andrés, Amado |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
| 700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
| 700 | 0 | |a REIPI, REDinREN, and GESITRA‐IC/SEIMC. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 95(2023), 5 vom: 01. Mai |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:5 |g day:01 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.02267-20 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 5 |b 01 |c 05 | ||